Levobupivacaine Molteni (Levobupivacaine)

Levobupivacaine works by reversibly blocking voltage‑gated sodium channels on neuronal membranes. This blockade prevents the initiation and propagation of action potentials, thereby inhibiting the transmission of pain signals from peripheral nerves to the central nervous system. The result is a loss of sensation in the targeted area while preserving motor function at lower concentrations.

The appropriate dose of Levobupivacaine Molteni is determined by the prescribing clinician based on the type of procedure, patient characteristics, and route of administration. Dosing guidelines are provided in the product’s prescribing information, but the final regimen must be individualized by the healthcare professional.

Safety data for levobupivacaine during pregnancy and lactation are limited. The drug may be used when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should assess each case carefully and follow local regulatory recommendations regarding use in pregnant or nursing patients.

To order Levobupivacaine Molteni, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both agents provide effective regional blocks, but levobupivacaine is often preferred when a safer cardiac profile is desired, especially in high‑risk patients.

Levobupivacaine Molteni should be stored below 25 °C in its original container, protected from moisture and direct light. The solution must be kept in a clean, dry environment and inspected for particulate matter before use. Do not freeze or shake the product, and follow standard aseptic techniques during preparation.

Levobupivacaine is administered by a qualified healthcare professional via injection. Common routes include epidural infusion, peripheral nerve block, infiltration of surgical sites, or intrathecal injection. The specific technique, volume, and concentration are chosen according to the intended clinical effect and patient factors.

The most serious risks include cardiovascular toxicity such as arrhythmias or cardiac arrest, and central nervous system toxicity manifesting as seizures or respiratory depression. Early signs of systemic toxicity—such as tinnitus, metallic taste, or circumoral numbness—should prompt immediate assessment and supportive measures.

Levobupivacaine should be avoided in patients with a known hypersensitivity to amide‑type local anesthetics, in individuals with severe cardiac conduction disorders without appropriate monitoring, and in patients where the risk of systemic toxicity outweighs the benefit. Caution is also advised for patients with significant hepatic impairment.